$BCLI
BRAINSTORM CELL THERAPEUTICS INC.

2022 Q3 Form 10-Q Financial Statement

#000141057822002510 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.065M $2.478M $2.859M
YoY Change 84.75% -1.74% 10.39%
% of Gross Profit
Research & Development $3.776M $5.113M $2.616M
YoY Change 4.37% 42.07% -39.74%
% of Gross Profit
Depreciation & Amortization $70.00K $71.00K $74.00K
YoY Change 4.48% 14.52% 21.31%
% of Gross Profit
Operating Expenses $3.776M $5.113M $2.616M
YoY Change 4.37% 42.07% -39.74%
Operating Profit -$6.841M -$7.591M -$5.475M
YoY Change 29.64% 24.02% -20.98%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$17.00K $550.0K $115.0K
YoY Change -71.19% -471.62% -57.41%
Pretax Income -$6.858M -$7.041M -$5.360M
YoY Change 28.52% 12.31% -19.52%
Income Tax
% Of Pretax Income
Net Earnings -$6.858M -$7.041M -$5.360M
YoY Change 28.52% 12.31% -19.54%
Net Earnings / Revenue
Basic Earnings Per Share -$0.19 -$0.19 -$0.15
Diluted Earnings Per Share -$0.19 -$0.19 -$0.15
COMMON SHARES
Basic Shares Outstanding 36.49M 36.49M 36.44M
Diluted Shares Outstanding 36.49M 36.49M 36.44M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.393M $12.24M $18.40M
YoY Change -73.42% -64.62% -54.06%
Cash & Equivalents $4.144M $9.005M $15.15M
Short-Term Investments $3.249M $3.239M $3.246M
Other Short-Term Assets $51.00K $445.0K $802.0K
YoY Change 2.0% 13.52% 9.86%
Inventory
Prepaid Expenses
Receivables $58.00K $117.0K $61.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $7.502M $12.81M $19.26M
YoY Change -73.15% -63.61% -53.06%
LONG-TERM ASSETS
Property, Plant & Equipment $1.003M $1.072M $1.124M
YoY Change -18.06% 1.71% 3.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.752M $6.155M $6.531M
YoY Change -12.77% -12.67% -13.39%
Total Long-Term Assets $5.752M $6.155M $6.531M
YoY Change -12.77% -12.67% -13.39%
TOTAL ASSETS
Total Short-Term Assets $7.502M $12.81M $19.26M
Total Long-Term Assets $5.752M $6.155M $6.531M
Total Assets $13.25M $18.96M $25.79M
YoY Change -61.62% -55.11% -46.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.395M $5.292M $4.570M
YoY Change 133.48% 76.4% 79.08%
Accrued Expenses $58.00K $44.00K $71.00K
YoY Change -85.01% -97.43% -95.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.948M $7.846M $7.372M
YoY Change 53.06% -2.64% -10.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.918M $3.264M $3.932M
YoY Change -22.52% -18.48% -5.93%
Total Long-Term Liabilities $2.918M $3.264M $3.932M
YoY Change -22.52% -18.48% -5.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.948M $7.846M $7.372M
Total Long-Term Liabilities $2.918M $3.264M $3.932M
Total Liabilities $11.87M $11.11M $11.30M
YoY Change 23.45% -7.9% -8.62%
SHAREHOLDERS EQUITY
Retained Earnings -$193.0M -$186.0M -$179.0M
YoY Change 15.57% 14.8% 14.93%
Common Stock $194.3M $193.9M $193.5M
YoY Change 0.99% 0.84% 0.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.388M $7.851M $14.49M
YoY Change
Total Liabilities & Shareholders Equity $13.25M $18.96M $25.79M
YoY Change -61.62% -55.11% -46.9%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$6.858M -$7.041M -$5.360M
YoY Change 28.52% 12.31% -19.54%
Depreciation, Depletion And Amortization $70.00K $71.00K $74.00K
YoY Change 4.48% 14.52% 21.31%
Cash From Operating Activities -$4.850M -$6.134M -$3.688M
YoY Change -24.92% 15.11% -58.88%
INVESTING ACTIVITIES
Capital Expenditures $1.000K $19.00K $9.000K
YoY Change -99.58% -32.14% -70.0%
Acquisitions
YoY Change
Other Investing Activities -$10.00K $7.000K -$8.000K
YoY Change -100.52% -187.5% -20.0%
Cash From Investing Activities -$11.00K -$12.00K -$17.00K
YoY Change -100.65% -69.23% -54.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $151.0M
YoY Change 0.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -4.850M -6.134M -3.688M
Cash From Investing Activities -11.00K -12.00K -17.00K
Cash From Financing Activities 0.000 0.000
Net Change In Cash -4.861M -6.146M -3.705M
YoY Change -0.18% 14.49% 95.41%
FREE CASH FLOW
Cash From Operating Activities -$4.850M -$6.134M -$3.688M
Capital Expenditures $1.000K $19.00K $9.000K
Free Cash Flow -$4.851M -$6.153M -$3.697M
YoY Change -27.56% 14.86% -58.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address Address Line1
EntityAddressAddressLine1
1325 Avenue of Americas, 28th Floor
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address City Or Town
EntityAddressCityOrTown
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10019
dei City Area Code
CityAreaCode
201
dei Local Phone Number
LocalPhoneNumber
488-0460
dei Security12b Title
Security12bTitle
Common Stock, $0.00005 par value
dei Trading Symbol
TradingSymbol
BCLI
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36461667
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36056391
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36486180
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36318561
dei Entity Central Index Key
EntityCentralIndexKey
0001137883
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
bcli Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
P15Y
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36401413
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36486180
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36641
dei Entity Registrant Name
EntityRegistrantName
BRAINSTORM CELL THERAPEUTICS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-7273918
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36486180
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9005000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18856000
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
3239000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
3238000
CY2022Q2 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
117000
CY2021Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
86000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
445000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1100000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
12806000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
23280000
CY2022Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
27000
CY2021Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
27000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5056000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4781000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1072000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1189000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6155000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5997000
CY2022Q2 us-gaap Assets
Assets
18961000
CY2021Q4 us-gaap Assets
Assets
29277000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5292000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3700000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
44000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
83000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1478000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1461000
CY2022Q2 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
1032000
CY2021Q4 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
1073000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7846000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6317000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3264000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3618000
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3264000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3618000
CY2022Q2 us-gaap Liabilities
Liabilities
11110000
CY2021Q4 us-gaap Liabilities
Liabilities
9935000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
12000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36486180
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36401413
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
193900000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
192990000
CY2022Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2021Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-185945000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-173544000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
7851000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
19342000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18961000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29277000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7729000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7940000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5113000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3599000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5337000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5110000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2478000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2522000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13066000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13050000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7591000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6121000
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
665000
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
119000
CY2022Q2 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-550000
CY2021Q2 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-148000
us-gaap Net Income Loss
NetIncomeLoss
-12401000
us-gaap Net Income Loss
NetIncomeLoss
-12931000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7041000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6269000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36461667
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36056391
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36486180
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36318561
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35464000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
290000
CY2021Q1 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
7104000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6662000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
36201000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
240000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6269000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
30172000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
19342000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
505000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5360000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
14487000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
405000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7041000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
7851000
us-gaap Profit Loss
ProfitLoss
-12401000
us-gaap Profit Loss
ProfitLoss
-13149000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-7041000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-6487000
us-gaap Depreciation
Depreciation
145000
us-gaap Depreciation
Depreciation
123000
CY2022Q2 us-gaap Depreciation
Depreciation
71000
CY2021Q2 us-gaap Depreciation
Depreciation
62000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
910000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
748000
CY2022Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
405000
CY2021Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
458000
bcli Increase Decrease In Operating Lease Expense Income
IncreaseDecreaseInOperatingLeaseExpenseIncome
-612000
bcli Increase Decrease In Operating Lease Expense Income
IncreaseDecreaseInOperatingLeaseExpenseIncome
-190000
CY2022Q2 bcli Increase Decrease In Operating Lease Expense Income
IncreaseDecreaseInOperatingLeaseExpenseIncome
-495000
CY2021Q2 bcli Increase Decrease In Operating Lease Expense Income
IncreaseDecreaseInOperatingLeaseExpenseIncome
103000
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-624000
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-727000
CY2022Q2 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-301000
CY2021Q2 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-405000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1592000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2417000
CY2022Q2 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
722000
CY2021Q2 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
448000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-80000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-139000
CY2022Q2 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-97000
CY2021Q2 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-318000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9822000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14297000
CY2022Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6134000
CY2021Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5329000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
58000
CY2022Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19000
CY2021Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
1000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
18000
CY2022Q2 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-7000
CY2021Q2 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
11000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-76000
CY2022Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12000
CY2021Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-39000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
bcli Proceeds From At Market
ProceedsFromAtMarket
7104000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7109000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9851000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7264000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6146000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5368000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18856000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37829000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15151000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35933000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9005000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30565000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9005000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30565000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-186000000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4742000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 58.3pt;"><b style="font-size:10pt;font-weight:bold;">D.     </b><b style="font-weight:bold;"> </b><b style="font-size:10pt;font-weight:bold;">Use of estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 82.8pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p>
bcli Percentage Of Royalty Payment If Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductCoveredByValidClaimOrOrphanDrugStatus
0.05
bcli Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
0.03
bcli Maturity Of Interest Bearing Bank Deposits
MaturityOfInterestBearingBankDeposits
P1Y6M
CY2021 bcli Maturity Of Interest Bearing Bank Deposits
MaturityOfInterestBearingBankDeposits
P1Y6M
CY2022Q2 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
362000
CY2021Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
1086000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5056000
us-gaap Operating Lease Payments
OperatingLeasePayments
1368000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y5M23D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0675
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
731000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1053000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1395000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1275000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
196000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4650000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
92000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4742000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10000000.0
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1250000
CY2020Q1 us-gaap Share Price
SharePrice
8.00
CY2020Q1 bcli Warrant Term
WarrantTerm
P3Y
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
250000
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15.00
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
151000000
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3037962
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
272596
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.49
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P1Y2M23D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
39767
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
47772
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
4.43
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
264591
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.32
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P1Y1M9D
us-gaap Share Based Compensation
ShareBasedCompensation
910000
us-gaap Share Based Compensation
ShareBasedCompensation
530000
CY2022Q2 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
7729000
CY2021Q2 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
8620000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7729000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7940000

Files In Submission

Name View Source Status
0001410578-22-002510-index-headers.html Edgar Link pending
0001410578-22-002510-index.html Edgar Link pending
0001410578-22-002510.txt Edgar Link pending
0001410578-22-002510-xbrl.zip Edgar Link pending
bcli-20220630.xsd Edgar Link pending
bcli-20220630x10q.htm Edgar Link pending
bcli-20220630xex31d1.htm Edgar Link pending
bcli-20220630xex31d2.htm Edgar Link pending
bcli-20220630xex32d1.htm Edgar Link pending
bcli-20220630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bcli-20220630_def.xml Edgar Link unprocessable
bcli-20220630_lab.xml Edgar Link unprocessable
bcli-20220630_pre.xml Edgar Link unprocessable
bcli-20220630_cal.xml Edgar Link unprocessable
bcli-20220630x10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable